Drug Search Results
More Filters [+]

HS-10390

Alternative Names: HS-10390, HS 10390, HS10390
Latest Update: 2023-07-13
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Changzhou Hengbang Pharmaceutical Co., Ltd./Shanghai Hansen Biomedical Technology Co., Ltd./Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for HS-10390

Countries in Clinic: China

Active Clinical Trial Count: 2

Highest Development Phases

Phase 1: Glomerulonephritis|Glomerulosclerosis, Focal Segmental|IgA Nephropathy

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

HS-10390-101

P1

Recruiting

Glomerulonephritis|Glomerulosclerosis, Focal Segmental|IgA Nephropathy

2024-02-16

CTR20230998

P1

Not yet recruiting

Glomerulosclerosis, Focal Segmental|IgA Nephropathy

None

Recent News Events

Date

Type

Title